Background: Specific HCMV IgE response has been reported by some authors, and was proposed as a valuable virologic marker of CMV infection.
Objectives: we evaluated specific HCMV IgE in renal transplant patients with active (primary and secondary) HCMV infection with special interest to symptomatic infections.
Study Design: Specific IgE was tested retrospectively by ELISA and immunoblot (IB) on sera of 55 RT patients who were followed before and after transplantation with virologic markers of CMV infection.
Results: Total serum IgE levels were similar in control group and in patients with primary and secondary HCMV infections. Anti-CMV specific IgE response by ELISA was more frequently found in patients with primary infection (76.9%) than in patients with secondary infection (47.1%). These specific IgE reacted on immunoblot with a 150 kDa protein in 84.6% of patients with primary infection and 94.1% with secondary infections; and reacted with rp52 (pUL44) in 76.9% of primary infection and 47.1% of secondary infection.
Conclusions: Anti-CMV specific IgE tested by immunoblot and ELISA is a marker of CMV infection. It was clearly detected in cases of active infection (primary and secondary) and was present in cases with severe CMV clinical manifestations. In contrast, anti-CMV specific IgE, was consistently negative among healthy blood donors. This is the first report of CMV proteins detected by IgE immunoblot.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0928-0197(96)00206-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of the new RIDA qLine Allergy multiparameter immunoblot and the ImmunoCAP Specific IgE test for the identification of clinically relevant food and aeroallergen allergies.
Front Allergy
January 2025
Department of Dermatology, Venereology and Allergology, University Medical Centre Goettingen, Goettingen, Germany.
Background: Multiparameter immunoblot testing is increasingly used as an alternative to multiple individual IgE analyses for type 1 allergies. This study investigated the performance of an inexpensive immunoblot method, the RIDA qLine allergy test system (R-Biopharm AG), vs. the current gold standard.
View Article and Find Full Text PDFA nomogram for predicting bladder dysfunction in patients with type 2 diabetes mellitus: a retrospective study.
PeerJ
January 2025
Department of Nursing, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.
Background: Diabetic bladder dysfunction (DBD) is a common urinary complication in diabetic patients, significantly affecting their overall well-being and quality of life, and placing a considerable burden on healthcare resources. Early prevention is crucial; however, the absence of a simple and effective tool to predict DBD onset remains a significant challenge. This study aims to identify risk factors for DBD in patients with type 2 diabetes mellitus (T2DM) and to develop a predictive nomogram for clinical application.
View Article and Find Full Text PDFTheoretical and practical considerations for validating antigen-specific B cell ImmunoSpot assays.
J Immunol Methods
January 2025
Research & Development Department, Cellular Technology Limited, Shaker Heights, OH 44122, USA. Electronic address:
Owing to their ability to reliably detect even very rare antigen-specific B cells in cellular isolates such as peripheral blood mononuclear cells (PBMC), and doing so robustly in a high throughput-compatible manner, B cell ELISPOT/FluoroSpot (collectively "B cell ImmunoSpot") tests have become increasingly attractive for immune monitoring in regulated settings. Presently, there are no guidelines for the qualification and validation of B cell ImmunoSpot assay results. Here, we propose such guidelines, building on the experience acquired from T cell ImmunoSpot testing in an environment adhering to the requirements of regulatory bodies yet taking the unique features of B cell assays into account.
View Article and Find Full Text PDFEffectiveness of Tralokinumab in Different Phenotypes of Atopic Dermatitis: A Real-World Study.
Dermatol Ther (Heidelb)
January 2025
Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", "Sapienza" University of Rome, Polo Pontino, 04100, Latina, Italy.
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and a relapsing course, affecting approximately 25% of children and 4-7% of adults. This study evaluated the efficacy, safety, and quality-of-life impact of tralokinumab, a humanized monoclonal antibody targeting interleukin-13 (IL-13), in treating moderate-to-severe AD in a real-world setting, with a focus on different AD phenotypes.
Methods: An observational cohort of 30 adults treated with tralokinumab for ≥ 16 weeks was analyzed.
The Role of TSLP and IL-1 β and Their Genetic Variants in the Pathogenesis of Single and Multiple Atopic Diseases in Children.
J Clin Med
January 2025
Department and Clinic of Paediatrics, Allergology and Cardiology, Wroclaw Medical University, ul. Chałubińskiego 2a, 50-368 Wrocław, Poland.
Allergic diseases commonly coexist, manifesting in a sequence described as the "allergic march". This study aimed to evaluate TSLP's and IL-1β's potential as biomarkers in both single and multi-pediatric atopic diseases like atopic eczema, food allergy, and anaphylaxis and analyze specific SNPs in the TSLP and IL-1β genes to determine their associations with their occurrence and severity. This analysis included 109 atopic children diagnosed with atopic dermatitis, food allergy, or anaphylaxis alongside a control group of 57 non-atopic children.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!